Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 2:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,486 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
Interventions
Azacitidine (Vidaza), Nab-paclitaxel (Abraxane)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Conditions
Advanced Solid Tumors
Interventions
IMC-1121B, 1121B
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Conditions
Neoplasm Malignant
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Conditions
Advanced Solid Tumors
Interventions
Treatment with ARQ 197 in combination with sorafenib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • Nashville, Tennessee
Conditions
Solid Tumors
Interventions
ORIC-114, Chemotherapy drug
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
17
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 14 more
Conditions
Cancer, Metastases
Interventions
panHer
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California
Conditions
Solid Tumor, Malignant Lymphoma, Tumor
Interventions
ARQ 092
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Miami, Florida + 3 more
Conditions
Advanced Solid Tumors
Interventions
Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more
Conditions
Cancers
Interventions
NM6603
Drug
Lead sponsor
NucMito Pharmaceuticals Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Nashville, Tennessee + 1 more
Conditions
Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Interventions
CTIM-76
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more
Conditions
Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Interventions
EMB-01
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Canton, Ohio
Conditions
Advanced Solid Tumor
Interventions
BGB-C354, Tislelizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Interventions
HBI-2438
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Encinitas, California • Glendale, California • Long Beach, California + 9 more
Conditions
Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, capecitabine, irinotecan hydrochloride, oxaliplatin
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Solid Tumors
Interventions
M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Tucson, Arizona • New Haven, Connecticut
Conditions
Solid Tumor
Interventions
PEGPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Santa Monica, California • Nashville, Tennessee
Conditions
RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Interventions
TAS0953/HM06
Drug
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
9
States / cities
Orange, California • Stanford, California • Boston, Massachusetts + 5 more
Conditions
Advanced Solid Tumors
Interventions
GS-0201, Sacituzumab Govitecan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Austin, Texas + 2 more
Conditions
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
SL-279252
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Cancer, Cancer, Lung
Interventions
CPO301
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois